RNA Analytical/Quality Videos

  1. Next-Gen Analytical Methods to Watch in mRNA-LNP Development 6/9/2026

    In the opening clip from this Advancing RNA Live event, AbbVie’s Elaine Peters, Sanofi’s Philippe Talaga, and Tessera’s Ilya Shestopalov share the novel methods they’ve been watching the most closely in the mRNA-LNP development space, as well as the role these methods will play in elucidating more about our drug products’ quality attributes. 

  2. AuroraTX: Ultra-Sensitive, Precise Structural Measurements Of Your Biomolecules 6/12/2025

    Gain key insights into your biomolecules' structure and stability with an advanced, automated measurement technique. Unlock precise, label-free analysis across diverse sample types and conditions.

  3. Analytical Limitations In Assessing Plasmid Quality for mRNA Production 4/11/2025

    There remain a lot of gaps in our understanding of plasmid quality, particularly for high-quality mRNA production (as opposed to viral vector production). In this segment of a recent Advancing RNA Live panel, speakers Adi Nair, Tyler Goodwin, and April Sena highlight their biggest questions around plasmid DNA quality, as well as the pros and cons of some of the analytical methods upon which we’re relying most heavily today to assess plasmid quality.

  4. How Is mRNA "Shaking Up" Our Regulatory Interactions & Operations Today? 5/10/2024

    The Advancing RNA Live panelists share several inconsistencies they’ve encountered working with global regulators, as well as on which aspects they’re seeing regulatory agencies applying greater scrutiny in mRNA development today.

  5. Select An Ion-Pairing Agent For Impurity Analysis Of Oligonucleotides 5/4/2022

    Learn about method development considerations when selecting an appropriate ion-pairing agent and impurity analysis of dye-conjugated oligonucleotides.

  6. How Can Sponsors & CDMOs Collaborate On RNA Analytical/Process Development? 8/22/2024

    Having worked on both the innovator and CDMO sides of the industry, Advancing RNA LIVE panelist Khaled Yamout outlines where he sees the greatest weaknesses in these critical sponsor-CDMO partnerships and offers guidance.

  7. LBA Vs. LC-MS: Competing Technologies At A Development Crossroad 2/6/2025

    Watch as bioanalytical experts Shane Karnik, MS, and Matt Hartle, Ph.D., explore why many sponsors are reevaluating the use of LBA for large molecule protein analysis in favor of LC-MS.

  8. A Novel Nuclease For CRISPR-Based Cell And Gene Therapies 10/28/2024

    Take an exploration of the therapeutic potential of hfCas12Max, showcasing its advantages over existing CRISPR nucleases and its role in accelerating the development of life-saving treatments.

  9. The Price of Progress: Unlocking Cost Efficiencies in mRNA-LNP Production 4/11/2025

    In this final segment of an Advancing RNA Live discussion, panelists April Sena, Tyler Goodwin, and Adi Nair share the most meaningful and manageable improvements the industry can be making today to upstream and downstream processes to drive down mRNA-LNP COGS.In this final segment of an Advancing RNA Live discussion, panelists April Sena, Tyler Goodwin, and Adi Nair share the most meaningful and manageable improvements the industry can be making today to upstream and downstream processes to drive down mRNA-LNP COGS.

  10. Where Does The mRNA Vaccine Regulatory Paradigm Fall Short For Therapeutics? 5/10/2024

    This Advancing RNA panel of experts sees a couple of important questions those striving to make RNA therapeutics will find themselves confronting when collaborating with regulators.